News & Media
News & Media
Kernal Biologics to Present at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
Kernal Biologics to Present at 3rd Annual mRNA-Based Therapeutics Summit
Kernal Biologics to Present at Locust Walk RNA Innovation Conference
Kernal Biologics to Present at Biotech Showcase
Kernal Biologics' mRNA 2.0 is featured on STAT
Kernal Biologics Announces Presentations at The International mRNA Health Conference
Pushing mRNA therapeutics for cancer, Cambridge startup nabs Series A to explore next-gen approach
Amgen-backed Kernal Biologics pops off with $25M for mRNA platform
Kernal Biologics Announces $25M Series A Financing to Advance its mRNA 2.0 Technology for Oncology
The Vast Promise of mRNA Technology
Wall Street Journal
Kernal Biologics Presenting Results at the 9th Annual mRNA Health Conference
Startups set off new wave of mRNA therapeutics
Kernal Biologics Enters Development Phase Reaching Critical Milestones for its First mRNA-Based Cancer-Therapeutic Product
Targeted delivery, oral vaccines and mRNA 2.0: The next generation of drugs and prophylactics in the fight against COVID-19
You've met Moderna, BioNTech and CureVac. Now meet Kernal Bio, the startup working on mRNA 2.0.
Kernal mRNAs are heading to space!
Kernal is accepted to MassBio's MassConnect Program
Kernal Biologics wins Amgen's coveted Golden Ticket award for the second year in a row
Kernal Biologics receives Technology in Space Award from CASIS & Boeing through MassChallenge
Can mRNA disrupt the drug industry?